Furthermore, inhibition of Treg-expressed CD27 acts synergistically with PD-1-checkpoint inhibition to improve CTL-mediated immunity against solid tumors (86), suggesting that CD27 is a useful marker in cancer immunotherapy. This evidence concerns the gene CD27 and cancer.